Actively Recruiting

Phase Not Applicable
Age: 0 - 5Months
All Genders
Healthy Volunteers
NCT06940713

Prospective Study of the Feasibility of Brain Connectivity Imaging by Functional Ultrasound Imaging (fUS) in Newborn Infant

Led by Institut National de la Santé Et de la Recherche Médicale, France · Updated on 2025-12-18

76

Participants Needed

1

Research Sites

226 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Neurodevelopmental disorders (NDD) affect how the brain develops and can lead to lifelong difficulties with movement, learning, behavior, and thinking. Every year, around one million newborns in Europe are affected by these conditions. Some babies are at higher risk of NDD due to factors such as being born extremely premature, having poor growth in the womb, experiencing a lack of oxygen at birth, or having a family history of severe NDD. However, predicting which babies will develop these disorders is currently very challenging because there are no reliable early indicators (biomarkers) to detect them. The CONEXUS study is testing a new type of brain imaging technology called functional ultrasound imaging (fUS) to see if it can help assess brain function in newborns at high risk of NDD. This technique measures brain activity by detecting small changes in blood flow, similar to an ultrasound scan but using advanced imaging technology. Researchers believe this method, known as fC-fUS imaging, could help identify early signs of neurodevelopmental disorders. Preliminary studies have shown that fUS imaging can detect brain activity changes in newborns, such as differences between sleep states or during epileptic seizures. The CONEXUS study will expand on this by improving the imaging technology and testing it in a larger group of newborns, including those born prematurely, those with restricted growth, those who needed cooling treatment after birth due to lack of oxygen, and those at risk for autism spectrum disorder (ASD). The study is being conducted in multiple hospitals in France over five years, involving newborn intensive care, pediatrics, and child psychiatry teams. It is a feasibility study, meaning researchers aim to test whether this imaging technique is practical and effective for use in newborns. Babies will have short, painless fUS scans that focus on brain regions involved in movement, hearing, vision, and attention. Ultimately, the goal of CONEXUS is to demonstrate that fC-fUS imaging can help doctors understand early brain development and identify signs of neurodevelopmental disorders before symptoms appear. If successful, this technique could improve early diagnosis, allowing doctors to start treatment sooner and improve long-term outcomes for affected children. This research has the potential to transform neonatal care by providing a new tool for detecting and monitoring brain function in newborns.

CONDITIONS

Official Title

Prospective Study of the Feasibility of Brain Connectivity Imaging by Functional Ultrasound Imaging (fUS) in Newborn Infant

Who Can Participate

Age: 0 - 5Months
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Premature babies born between 23 weeks and 5 days and 27 weeks and 6 days gestational age (extremely preterm) or between 28 weeks and 0 days and 31 weeks and 6 days gestational age (very preterm).
  • Newborns older than 36 weeks gestational age with neonatal anoxic-ischemic encephalopathy treated with therapeutic hypothermia.
  • Babies born between 32 weeks and 0 days and 40 weeks and 6 days gestational age with intrauterine growth restriction (birth weight or head circumference below 10th percentile).
  • Babies younger than 6 months who have a sibling with autism spectrum disorder.
  • Term newborns between 39 weeks and 0 days and 40 weeks and 6 days gestational age without pregnancy complications, with normal birth measurements and Apgar score greater than 6 at 10 minutes.
  • Parental consent given.
  • Baby covered by or receiving social security.
Not Eligible

You will not qualify if you...

  • Person under judicial protection measures such as guardianship, curatorship, or safeguard of justice.
  • Known malformative pathology.
  • Known chromosomal abnormality.
  • Known allergy to silicone.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hôpital Robert Debré

Paris, France, 75019

Actively Recruiting

Loading map...

Research Team

V

Valerie BIRAN, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DEVICE_FEASIBILITY

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here